PURPOSE: N-myc downstream regulated gene 1 (NDRG1) markedly reduces metastasis of numerous tumors. However, NDRG1's function in malignant tumors has not been fully determined. Therefore, we investigated the association of NDRG1 expression with clinical outcomes in neuroblastoma (NB) patients. METHODS: We obtained total RNA from residual cancer cells using microdissection from NB patients. Furthermore, we examined the expression of NDRG1 in NB patients using immunohistochemical staining. RESULTS: Of the 48 patients observed, low NDRG1 expression was associated with poor prognostic factors such as primary tumor size and MYCN amplification. Low expression of NDRG1 was associated with a poor prognosis (p = 0.001) and multivariate analysis identified low expression of NDRG1 as an independent risk factor for predicting poor prognosis in NB patients. Furthermore, in the MYCN non-amplification group (n = 33), low expression of NDRG1 was associated with a poor prognosis (p = 0.001). Immunohistochemical analysis showed NDRG1 expression at the plasma membranes of NB cells. NDRG1 expression levels were also correlated with expression of NDRG1 mRNA. CONCLUSION: We confirmed that low NDRG1 expression is a significant and independent prognostic indicator in NB by multivariate analysis. Furthermore, NDRG1 may be a novel prognostic marker in MYCN non-amplification NB patients.
PURPOSE:N-myc downstream regulated gene 1 (NDRG1) markedly reduces metastasis of numerous tumors. However, NDRG1's function in malignant tumors has not been fully determined. Therefore, we investigated the association of NDRG1 expression with clinical outcomes in neuroblastoma (NB) patients. METHODS: We obtained total RNA from residual cancer cells using microdissection from NB patients. Furthermore, we examined the expression of NDRG1 in NB patients using immunohistochemical staining. RESULTS: Of the 48 patients observed, low NDRG1 expression was associated with poor prognostic factors such as primary tumor size and MYCN amplification. Low expression of NDRG1 was associated with a poor prognosis (p = 0.001) and multivariate analysis identified low expression of NDRG1 as an independent risk factor for predicting poor prognosis in NB patients. Furthermore, in the MYCN non-amplification group (n = 33), low expression of NDRG1 was associated with a poor prognosis (p = 0.001). Immunohistochemical analysis showed NDRG1 expression at the plasma membranes of NB cells. NDRG1 expression levels were also correlated with expression of NDRG1 mRNA. CONCLUSION: We confirmed that low NDRG1 expression is a significant and independent prognostic indicator in NB by multivariate analysis. Furthermore, NDRG1 may be a novel prognostic marker in MYCN non-amplification NB patients.
Authors: N van Belzen; W N Dinjens; M P Diesveld; N A Groen; A C van der Made; Y Nozawa; R Vlietstra; J Trapman; F T Bosman Journal: Lab Invest Date: 1997-07 Impact factor: 5.662
Authors: Takehiko Segawa; Martin E Nau; Linda L Xu; Rao N Chilukuri; Mazen Makarem; Wei Zhang; Gyorgy Petrovics; Isabell A Sesterhenn; David G McLeod; Judd W Moul; Maryanne Vahey; Shiv Srivastava Journal: Oncogene Date: 2002-12-12 Impact factor: 9.867
Authors: Christopher R Bohl; Sitaram Harihar; Warren L Denning; Rahul Sharma; Danny R Welch Journal: J Mol Med (Berl) Date: 2013-12-06 Impact factor: 4.599
Authors: Yukiko Kiniwa; Jiang Li; Mingjun Wang; Chuang Sun; Jeffrey E Lee; Rong-Fu Wang; Helen Y Wang Journal: PLoS One Date: 2015-05-20 Impact factor: 3.240
Authors: Susanna Ambrosio; Stefano Amente; Carmen D Saccà; Mario Capasso; Raffaele A Calogero; Luigi Lania; Barbara Majello Journal: Oncotarget Date: 2017-01-17
Authors: Maria Krchniakova; Silvia Paukovcekova; Petr Chlapek; Jakub Neradil; Jan Skoda; Renata Veselska Journal: Front Pharmacol Date: 2022-09-07 Impact factor: 5.988